WORP VAN DER, H. B,, M. R. MACLEOD, P. M. W. BATH, R. BATHULA, H. CHRISTENSEN, B. COLAM, C. CORDONNIER, J. DEMOTES-MAINARD, I. DURAND-ZALESKI, C. GLUUD, J. C. JAKOBSEN, B. KALLMUNZERI, R. KOLLMAR, D. W. KRIEGER, K. R. LEES, D. MICHALSKI, C. MOLINA, J. MONTANER, R. O. ROINE, J. PETERSSON, R. PERRY, N. SPRIGG, D. STAYKOV, I. SZABO, G. VANHOOREN, J. M. WARDLAW, P. WINKEL, S. SCHWAB, S. SCHWAB, C. HOBOHM, H. SCHNEIDER, K. WARTENBERG, J. BERROUSCHOT, M. LORENZ, H. C. CHRISTENSEN, N. SPRIGG, R. BATHULA, P. FITZSIMMONS, R. PERRY, K. SAASTAMOINEN, B. C. CREAGH-BROWN, A. SWEENIE, R. LINDERT, M. RUBIERA, J. SERENAL, G. VANHOOREN, P. DESFONTAINES, C. CORDONNIER, I. SIBON, D. JATUZIS and F. ORZI. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. EUROPEAN STROKE JOURNAL. LONDON: SAGE PUBLICATIONS LTD, 2019, vol. 4, No 3, p. 254-262. ISSN 2396-9873. Available from: https://dx.doi.org/10.1177/2396987319844690.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial
Authors WORP VAN DER, H. B,, M. R. MACLEOD, P. M. W. BATH, R. BATHULA, H. CHRISTENSEN, B. COLAM, C. CORDONNIER, J. DEMOTES-MAINARD, I. DURAND-ZALESKI, C. GLUUD, J. C. JAKOBSEN, B. KALLMUNZERI, R. KOLLMAR, D. W. KRIEGER, K. R. LEES, D. MICHALSKI, C. MOLINA, J. MONTANER, R. O. ROINE, J. PETERSSON, R. PERRY, N. SPRIGG, D. STAYKOV, I. SZABO, G. VANHOOREN, J. M. WARDLAW, P. WINKEL, S. SCHWAB, S. SCHWAB, C. HOBOHM, H. SCHNEIDER, K. WARTENBERG, J. BERROUSCHOT, M. LORENZ, H. C. CHRISTENSEN, N. SPRIGG, R. BATHULA, P. FITZSIMMONS, R. PERRY, K. SAASTAMOINEN, B. C. CREAGH-BROWN, A. SWEENIE, R. LINDERT, M. RUBIERA, J. SERENAL, G. VANHOOREN, P. DESFONTAINES, C. CORDONNIER, I. SIBON, D. JATUZIS and F. ORZI.
Edition EUROPEAN STROKE JOURNAL, LONDON, SAGE PUBLICATIONS LTD, 2019, 2396-9873.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00121485
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/2396987319844690
UT WoS 000485316800007
Keywords in English Ischaemic stroke; randomised trial; treatment; hypothermia; cooling
Tags Excelence Science, FNUSA, RIV, rivok, Stroke, user
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/4/2021 09:48.
Abstract
Introduction We assessed whether modest systemic cooling started within 6 hours of symptom onset improves functional outcome at three months in awake patients with acute ischaemic stroke. Patients and methods In this European randomised open-label clinical trial with blinded outcome assessment, adult patients with acute ischaemic stroke were randomised to cooling to a target body temperature of 34.0-35.0 degrees C, started within 6 h after stroke onset and maintained for 12 or 24 h , versus standard treatment. The primary outcome was the score on the modified Rankin Scale at 91 days, as analysed with ordinal logistic regression. Results The trial was stopped after inclusion of 98 of the originally intended 1500 patients because of slow recruitment and cessation of funding. Forty-nine patients were randomised to hypothermia versus 49 to standard treatment. Four patients were lost to follow-up. Of patients randomised to hypothermia, 15 (31%) achieved the predefined cooling targets. The primary outcome did not differ between the groups (odds ratio for good outcome, 1.01; 95% confidence interval, 0.48-2.13; p = 0.97). The number of patients with one or more serious adverse events did not differ between groups (relative risk, 1.22; 95% confidence interval, 0.65-1.94; p = 0.52). Discussion In this trial, cooling to a target of 34.0-35.0 degrees C and maintaining this for 12 or 24 h was not feasible in the majority of patients. The final sample was underpowered to detect clinically relevant differences in outcomes. Conclusion Before new trials are launched, the feasibility of cooling needs to be improved.
Links
90090, large research infrastructuresName: CZECRIN II
PrintDisplayed: 27/4/2024 03:10